You are here
ADAPTIVE BIOTECHNOLOGIES CORPORATION
UEI: DMW5BNQ331K9
# of Employees: 0
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Correlating TCR diversity to immune reconstitution after cord blood transplant
Amount: $519,759.00DESCRIPTION provided by applicant Many patients requiring stem cell transplantation for hematological malignancies are unable to find a suitable HLA matched sibling or unrelated donor Transplants ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Non-invasive Diagnostic Platform Development for Celiac Disease Remission Status
Amount: $244,699.00DESCRIPTION (provided by applicant): The purpose of this proposal is to adapt a technology that we have developed for monitoring residual disease in leukemia patients to monitor residual autoimmune di ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling
Amount: $165,191.00DESCRIPTION (provided by applicant): Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling T-cell neoplasms are generally more aggressive and have poorer outcomes than comparable ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
Correlating TCR diversity to immune reconstitution after cord blood transplant
Amount: $2,528,467.00DESCRIPTION (provided by applicant): Many patients requiring stem cell transplantation for hematological malignancies are unable to find a suitable HLA-matched sibling or unrelated donor. Transplants ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION MEDICINE
Amount: $266,199.00Immunotherapy has emerged as a promising method to treat several cancers. In 2012 the FDA approved a new immunotherapy agent, ipilimumab, for metastatic melanoma. Ipilimumab activates T-cells and glob ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
Correlating TCR diversity to immune reconstitution after cord blood transplant
Amount: $148,999.00DESCRIPTION (provided by applicant): The goal of this Phase I project is to develop a method to objectively measure immune reconstitution following hematopoietic stem cell transplantation using direc ...
SBIRPhase I2011Department of Health and Human Services National Institutes of Health -
Development of T-cell receptor repertoire profiling as a diagnostic for T1D
Amount: $632,685.00DESCRIPTION (provided by applicant): The goal of this Phase I project is the identification of a molecular signature in the T-cell receptor repertoire of early-stage Type 1 Diabetes (T1D) patients th ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health
